Product Description
APL-102 is an oral, small molecule multi-tyrosine kinase inhibitor (MTKI) targeting several key oncogenic drivers. APL-102 may inhibit tumor angiogenesis and tumor cell growth by inhibiting VEGFR pathway and B-RAF/C-RAF/MAPK pathway. (Sourced from: https://www.apollomicsinc.com/pipeline-drugs/apl-102/)
Mechanisms of Action: CSF-1R Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Apollomics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05055518 |
APL-102-01 | P1 |
Suspended |
Oncology Solid Tumor Unspecified |
2028-10-31 |
50% |
2025-06-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/10/2021 |
News Article |
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102 |
|
11/12/2020 |
News Article |
Apollomics, Inc. Receives China Investigational New Drug Approval for APL-102 to Initiate a Phase 1 Study |
|
04/01/2019 |
News Article |
Apollomics, Inc. Presents Positive Preclinical Data on APL-102, an oral Multi-Kinase Inhibitor with CSF-1R Activity |